New scoping review of 8 rare tumor risk syndromes maps evidence on cancer risk and surveillance, revealing lifetime risks approaching 100% in some syndromes. Still, critical gaps in longitudinal and comparative data hinder cost-effectiveness evaluations. #HEOR #CancerRisk jheor.org/article/167564
